Novartis AG (NVS) Market Performance Overview - May 18, 2026
Novartis AG (NVS) closed at a price of $149.15, marking an increase of $1.07 or 0.72% from the previous close of $148.08. The stock opened at $149.01 and traded within a range of $148.95 to $150.58 during the day. The total trading volume for the session was approximately 1.62 billion shares, indicating significant market activity.
Financial Highlights
The Q1 2026 financial report details a mixed performance for Novartis:
- Total net sales reached $13.1 billion, a decrease of 1% year-over-year, with a 5% decline on a constant currency basis.
- U.S. sales declined 13% to $5.0 billion, while international sales outside the U.S. increased 8% to $8.2 billion.
- Operating income dropped 9% to $4.2 billion, and core operating income fell 12% to $4.9 billion.
- Net income stood at $3.2 billion, down 13% year-over-year, with basic earnings per share (EPS) decreasing 10% to $1.65.
- Free cash flow was reported at $3.3 billion, representing a 2% decrease compared to the previous year.
Product Performance and Launches
Product revenue trends varied notably across segments:
- Entresto: Sales decreased sharply by 42% to $1.3 billion, mainly due to increased generic competition in the U.S.
- Leqvio: Sales surged 76% to $452 million, supported by its inclusion in China’s National Reimbursement Drug List.
- Cosentyx: Maintained stable sales of $1.6 billion in the immunology segment.
- Xolair: Sales declined 15% to $388 million, impacted by biosimilar competition.
- Kesimpta: Neuroscience product sales rose 29% to $1.2 billion.
- Kisqali: Oncology segment product achieved robust growth, with sales increasing 59% to $1.5 billion.
Regulatory Approvals and Strategic Moves
Novartis made several key regulatory and strategic advances:
- Received FDA approvals for Cosentyx for hidradenitis suppurativa and pediatric indications.
- Approved Zolgensma for spinal muscular atrophy in Japan.
- Preparing regulatory submissions for Fabhalta in IgA nephropathy and Leqvio for pediatric hypercholesterolemia.
- Completed acquisition of Avidity Biosciences in February 2026 for approximately $12 billion, strengthening RNA therapeutics capabilities for rare diseases.
- Pending acquisitions include Excellergy, Inc. and Pikavation Therapeutics, Inc., subject to milestone achievements.
Market Sentiment and Investor Implications
Investor sentiment today appears cautiously optimistic, influenced by the following factors:
- Robust product pipeline and strategic acquisitions supporting growth prospects.
- Pressure on core products like Entresto and Xolair due to competitive challenges impacting revenues.
- Declines in net income and EPS could raise concerns about near-term profitability and revenue stability.
- Positive market reaction to recent strategic initiatives and regulatory milestones.
- Focus on the company’s ability to capitalize on emerging market opportunities and new product launches will be critical for future performance.
In conclusion, Novartis AG’s stock performance today reflects a balance of positive strategic developments alongside operational challenges. Monitoring product performance trends and regulatory progress will remain key for investors assessing the company’s longer-term outlook.
Explore more exclusive insights at nextfin.ai.
